Back to Search Start Over

Comparison of Radiofrequency Ablation and Microwave Ablation for the Management of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors :
Shaqran TM
Alharbi J
Al-Hunbusi SK
Alharbi RA
Alawaji M
Diqarshawi AM
Almokhlef RJ
Alfaqih AA
Alhumaidi RA
Alzahrani HA
Alzyad IM
Alwusaybie ZS
Alotaibi NM
Alzahrani NJ
Source :
Cureus [Cureus] 2024 Aug 27; Vol. 16 (8), pp. e67938. Date of Electronic Publication: 2024 Aug 27 (Print Publication: 2024).
Publication Year :
2024

Abstract

Hepatocellular carcinoma (HCC) is a common critical type of hepatic cancer worldwide. Recent guidelines have considered ablative therapeutic approaches as the primary option for managing early-stage surgically untreatable HCC. Among these therapies, radiofrequency ablation (RFA) and microwave ablation (MWA) have attained a significant role due to their efficacy and theoretical advantages. This review aims to compare and analyze the efficacy and safety of two common modalities, i.e., MWA and RFA, in the management of HCC. The literature search included PubMed, Cochrane Central Register of Controlled Trials, Medline, and Ovid for articles published until 2024. The outcomes included the local tumor progression (LTP), complete ablation (CA), the overall survival (OS) rate, or major complications. A meta-analysis was performed using Review Manager 5.3. The systematic review included six randomized controlled trials, including 826 patients. The findings revealed that MWA resulted in lower LTP and higher CA rates compared to RFA. However, the effect of complications was higher in the MWA therapy group. Despite that, the differences between all parameters were not significant. Statistical significance was not evident in the OS rates between the two modalities. Three studies found comparable survival rates between the two modalities, while one study reported similar local tumor recurrence-free survival rates between the two approaches. Both techniques appear to be effective and safe for the management of liver tumors, providing clinicians with valuable options for personalized patient care. Further high-quality research is needed to confirm these findings and guide clinical decision-making.<br />Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.<br /> (Copyright © 2024, Shaqran et al.)

Details

Language :
English
ISSN :
2168-8184
Volume :
16
Issue :
8
Database :
MEDLINE
Journal :
Cureus
Publication Type :
Academic Journal
Accession number :
39328664
Full Text :
https://doi.org/10.7759/cureus.67938